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Asthma is now one of the most common chronic diseases in Western countries and 
is characterized by reversible airway obstruction, bronchial hyperresponsiveness and 
airway inﬂ  ammation. For many years, anti-inﬂ  ammatory therapy in asthma has been 
largely reliant on glucocorticoids (GCs) – particularly in their inhaled form – and their 
use is associated with a striking reduction in the numbers of activated eosinophils, 
mast cells, and T cells in vivo. However, although GCs can be efﬁ  cacious, they are 
also rather nonspeciﬁ  c in their actions and may not be of beneﬁ  t to patients with severe 
asthma who experience virally-induced exacerbations of their disease. Their use also 
raises concerns regarding side effects and compliance particularly in children and 
adolescents. Furthermore, even in cases of good compliance, patients with moderate 
and severe asthma may experience signiﬁ  cant residual symptoms including exacerba-
tions of their disease that in some cases can be life-threatening (Walsh 2006). There 
is therefore a clear need for the development of more effective and targeted therapy 
for asthma.
Allergic asthma is the most common form of the disease and is characterized by 
elevated titres of speciﬁ  c immunoglobulin E (IgE) to common environmental allergens. 
Thus, one approach to asthma therapy is to block the effects of IgE. Omalizumab is 
an anti-IgE monoclonal neutralizing antibody that binds IgE at the same site (Cε3 
domain of the Fc fragment) as the IgE high afﬁ  nity receptor (FcεRI) expressed by 
mast cells and basophils. This results in inhibition of degranulation and synthesis of 
newly generated chemical mediators by IgE-sensitized mast cells and basophils. In 
the current issue of Therapeutics and Clinical Risk Management, Gennaro D’Amato 
and colleagues have provided a comprehensive review of the use of omalizumab in 
the treatment of allergic asthma. Careful analysis of published clinical trials by the 
authors reveals positive beneﬁ  ts on asthma symptoms together with a corticosteroid 
sparing effect, reduced use of bronchodilators and improved quality of life in patients 
with asthma. Importantly, omalizumab is effective in those patients with severe per-
sistent allergic asthma that is inadequately controlled by currently available asthma 
medication. Interestingly, it appears that in addition to its direct effects on basophils 
and mast cells, omalizumab also inhibits activation of eosinophils, T lymphocytes, 
and B lymphocytes which are fundamental to the chronic inﬂ  ammatory response in 
allergic diseases such as asthma. The authors’ conclusion is that omalizumab offers 
both therapeutic and economic value and represents a major advance for the treatment 
of patients with inadequately controlled severe persistent allergic asthma. Omalizumab 
appears to be well tolerated with few side-effects reported in published studies. How-
ever, more long-term studies are needed to fully elucidate the beneﬁ  t and safety of 
anti-IgE therapy in asthma.
Many mediators contribute to the pathophysiology of asthma thus development 
of speciﬁ  c antagonists directed at these substances represents an attractive target for 
inﬂ  ammation resolution. However, it is unlikely that a single antagonist will have a 
major clinical effect compared with nonspeciﬁ  c agents such as corticosteroids. Indeed, 
strategies to block a single mediator such as PAF antagonists, thromboxane inhibitors, 
and bradykinin antagonists have all proved to be disappointing (Barnes 2000). The 
cysteinyl leukotrienes (LTC4, LTD4, and LTE4) induce bronchoconstriction and are 
highly potent mediators of airway inﬂ  ammation. The cysteinyl leukotriene receptor 
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antagonists were the ﬁ  rst new class of anti-asthma drugs to 
be introduced in the last 30 years and are now an established 
part of the treatment of adult asthma. Overall, they are less 
effective than inhaled corticosteroids but some patients show 
a striking improvement and a corticosteroid-sparing effect 
has been demonstrated (Lipworth 1999). Three drugs of this 
class are in use at present: zaﬁ  rlukast, pranlukast, and monte-
lukast. All three are speciﬁ  cally active against the cysteinyl 
leuko-trienes by blocking their receptor, CysLT1. 
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